Pacira BioSciences
PCRX
235 hedge funds and large institutions have $1.26B invested in Pacira BioSciences in 2025 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 83 increasing their positions, 79 reducing their positions, and 31 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
39% more call options, than puts
Call options by funds: $4.04M | Put options by funds: $2.92M
34% more capital invested
Capital invested by funds: $941M → $1.26B (+$317M)
1.22% more ownership
Funds ownership: 108.12% → 109.34% (+1.2%)
10% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 31
5% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 79
1% more funds holding
Funds holding: 233 → 235 (+2)
Top Buyers
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$31.3M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$30.7M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$27.1M |
| 4 |
JGC
J. Goldman & Co
New York
|
+$17.5M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$12.7M |
Top Sellers
| 1 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$63.7M |
| 2 |
Millennium Management
New York
|
-$27.3M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$22.8M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$20.3M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$13.9M |
PCRX Hedge Fund Activity: Q1 2025 in Review
235 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q1 2025, worth a combined $1.26B — up 34% from $941M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new PCRX positions and 31 closed out — a net gain of 3 holders — while 83 added to existing stakes and 79 trimmed.
The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $31.3M. The largest seller was Pacer Advisors, cutting an estimated $63.7M.
- 235 institutional investors held Pacira BioSciences (PCRX) as of Q1 2025, up from 233 in Q4 2024.
- Funds reported $1.26B of Pacira BioSciences stock for Q1 2025, up 34% quarter-over-quarter.
- 34 funds opened new Pacira BioSciences positions in Q1 2025 and 31 closed out, a net change of +3 holders.
- The largest Pacira BioSciences buyer in Q1 2025 was Alyeska Investment Group, an estimated $31.3M added.
- The largest Pacira BioSciences seller in Q1 2025 was Pacer Advisors, an estimated $63.7M sold.
Based on aggregated 13F filings for Q1 2025.